Chemotherapy-induced immunomodulation in non-small-cell lung cancer: A rationale for combination chemoimmunotherapy

Hua Zheng, Masha Zeltsman, Marjorie G. Zauderer, Takashi Eguchi, Raj G. Vaghjiani, Prasad S. Adusumilli

Research output: Contribution to journalReview articlepeer-review


Spurred by the survival benefits seen with the use of checkpoint blockade in non-small-cell lung cancer (NSCLC), there has been a growing interest in the potential applications of immunotherapy. Despite this, the objective response rate for single-agent immunotherapy remains ≤20% in patients with advanced NSCLC. A combinatorial approach that utilizes both chemotherapy and immunotherapy is a potential strategy to increase antitumor efficacy. Accumulating evidence has shown that the immunomodulatory effects of chemotherapeutic agents can be exploited in a combinational approach. Herein, we review the influence of specific chemotherapeutic agents on the tumor immune microenvironment in preclinical and clinical studies, and establish the rationale for combination chemoimmunotherapy for the treatment of NSCLC.

Original languageEnglish (US)
Pages (from-to)913-927
Number of pages15
Issue number11
StatePublished - Sep 2017
Externally publishedYes


  • chemotherapy
  • immunomodulation
  • immunotherapy
  • microenvironment
  • non-small-cell lung cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Chemotherapy-induced immunomodulation in non-small-cell lung cancer: A rationale for combination chemoimmunotherapy'. Together they form a unique fingerprint.

Cite this